Botensilimab

Phase 3

AGENUS INC (AGEN)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Sep '27

AGENPhase 2$385M

Botensilimab Phase 2 Est. Readout

Botensilimab• Metastatic Pancreatic Ductal Adenocarcinoma234

Sep 2027~Estimated

CT.gov

00%

Q2 '27

AGENPhase 2$385M

Botensilimab Phase 2 Est. Readout (RECTIFY-1)

Botensilimab• Metastatic Pancreatic Ductal Adenocarcinoma16

Q2 2027~QEstimated

CT.gov

00%

Dec '26

AGENPhase 2$385M

Botensilimab Phase 2 Est. Readout

Botensilimab• Metastatic Pancreatic Ductal Adenocarcinoma24

Dec 2026~Estimated

CT.gov

00%

Competitive Landscape

0 competitors in Metastatic Pancreatic Ductal Adenocarcinoma

View Full Landscape

Drug Information

Target Indication

Metastatic Pancreatic Ductal Adenocarcinoma

Clinical Trial

NCT05630183

Last updated: 10/17/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

AGEN

AGENUS INC

Biological Products, (No Diagnostic Substances)•North America•NASDAQ

Related Pipeline

FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)Phase 3

Resectable MMR-deficient Solid Tumors

autologous human tumor-derived HSPPC-96Phase 3

Renal Cell Carcinoma

BalstilimabPhase 3

Advanced Melanoma

HSPPC-96 or OncophagePhase 3

Malignant Melanoma

Folfox ProtocolPhase 3

Gastric Cancer

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts